Zydus Cadila, through its wholly-owned subsidiary Zydus Healthcare, has acquired six brands from global pharma major MSD and its subsidiaries. The brands include Deca-durabolin, Durabolin, Sustanon, Multiload, Sicastat and Axeten range, which fall in the men’s health, women’s health, cardiovascular and wound management therapy segments. The deal includes transfer of distribution and commercialization rights and assignment of trademarks of all the six brands to Zydus Healthcare in India.
As part of the deal, Organon (India), one of the legal subsidiaries through which MSD operates its business in India, has also transferred the distribution and commercialization rights for Deca-Durabolin and Durabolin to Zydus for Nepal.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. It is the only Indian pharma company to launch its own patented NCE - Lipaglyn, the world’s first drug to be approved for the treatment of diabetic dyslipidemia.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1794.30 |
| Dr. Reddys Lab | 1275.05 |
| Cipla | 1383.00 |
| Zydus Lifesciences | 1105.65 |
| Lupin | 2274.00 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: